Food News and Research

RSS

Pennsylvania health giant reports $93 million profit as outpatient demand surges

Pittsburgh Tribune-Review: "Health giant UPMC will add 815 new full-time jobs through next June, officials announced yesterday after posting a strong first-quarter income. More than half of the jobs -- or about 430 -- will be throughout UPMC's network of 20 hospitals. They include physicians, nurses, food service workers, housekeepers and administrators, said Rob DeMichiei, senior vice president and chief financial officer.

12 Nov 2010

Research roundup: Doctors' industry ties; Patient safety and residents' hours; Designing a medical home

Archives of Internal Medicine: Physician Professionalism And Changes in Physician-Industry Relationships From 2004 to 2009 -"During the last 6 years a number of efforts have aimed to reduce, and in some cases eliminate, certain types of physician-industry relationships (PIRs)," including policies "that forbid physicians from accepting samples and receiving food and beverages in offices, limiting company representatives' access to physicians' offices and clinical areas, and banning faculty participation in speaker bureaus and other forms of promotional activity," write the authors.

12 Nov 2010

Derma Sciences net sales for third quarter 2010 increase 17% to $15,096,134

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and nine months ended September 30, 2010.

12 Nov 2010

Agilent fourth quarter revenues increase 35% to $1.58 billion

Agilent Technologies Inc. today reported revenues of $1.58 billion for the fourth fiscal quarter ended Oct. 31, 2010, 35 percent above one year ago, or 26 percent excluding the effects of the Varian acquisition and recent divestitures. Fourth-quarter GAAP net income was $232 million, or $0.66 per diluted share. Last year's fourth-quarter GAAP net income was $25 million, or $0.07 per share.

12 Nov 2010

Labopharm receives notice of Activis' ANDA submission for generic OLEPTRO

Labopharm Inc. today announced that on November 11, 2010 it received notice from Actavis South Atlantic LLC advising that Actavis has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 150 and 300 mg generic versions of OLEPTRO™ (trazodone hydrochloride extended-release 150 and 300 mg tablets) in the United States.

12 Nov 2010

Soligenix third quarter revenues increase to $861,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the third quarter of 2010.

12 Nov 2010

Plant-based respiratory allergies on the rise due to climate change

Bad news for 35 million allergy sufferers - ragweed, fungal spores and poison ivy are thriving due to rising carbon dioxide levels. At the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, Nov. 11-16, allergists and scientists discussed the effects of rising CO2 levels and a changing climate on plant biology and public health.

12 Nov 2010

Dreaded cod liver oil in a variety of flavours

The stomachs of the generation of 50 year olds and above, will be churning at the thought of their parents and grandparents serving up spoonfuls of the much dreaded cod liver oil. As a practice, parents giving their children cod liver oil has all but died, and yet, as a population, we have seen more and more inflammatory conditions effect people's lives, which are due in no small part to the 'modern day diet', which many of us live.

12 Nov 2010

Results of RE-LY trial evaluating Pradaxa capsules to be presented at American Heart Association Session

Results of two pre-specified sub-study analyses of the 18,113 patient RE-LY trial, involving the newly approved oral anticoagulant Pradaxa (dabigatran etexilate mesylate) capsules, will be presented at the American Heart Association's Annual Scientific Sessions on Monday, November 15, 2010.

12 Nov 2010

ACAAI scientific meeting to discuss pediatric allergies

Your child may be allergic to your holiday pumpkin pie, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, Nov. 11-16. Hot topics discussed in pediatric allergies include pumpkin and caterpillar allergies, and outgrowing childhood allergies.

12 Nov 2010

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

The 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) brings together leading allergists and immunologists from around the world.

12 Nov 2010

FDA unveils graphic anti-smoking warnings for cigarette packages

The Washington Post: "Federal health officials Wednesday unveiled plans to replace the warnings cigarette packs began carrying 25 years ago with new versions using images that could include emaciated cancer patients, diseased organs and corpses. Public health authorities and anti-smoking advocates hailed the move as a milestone in the battle against tobacco in the United States that began in 1964 when the surgeon general first declared cigarettes a public health threat.

12 Nov 2010

Weight bullying develops negative self image among children

Bullying about weight is not uncommon. Remuda Ranch Programs for Eating and Anxiety Disorders reports when children are teased about their weight, they are more reluctant to exercise or engage in physical activity.

12 Nov 2010

SLIT immunotherapy effective for long-term remission of bothersome allergy symptoms

Antihistamines and nasal steroids offer good short-term options for people with mild allergy, but allergy immunotherapy, better known as "allergy shots," is a preferred method for achieving long term remission of more bothersome allergy symptoms. Allergists mark the 100th anniversary of immunotherapy and present the latest advances at the American College of Allergy, Asthma and Immunology (ACAAI) annual scientific meeting in Phoenix, Nov. 11-16.

12 Nov 2010

Ordway, Milestone to develop drug formulation for administration through CompuFlo injection technology

Milestone Scientific Inc., the recognized leader in advanced, computer controlled drug delivery technologies, and Ordway Research Institute, a leading research and drug development organization, have agreed to develop drug formulations for precise targeted delivery of drugs to affected body parts, organs and cancerous tissue through Milestone's patented CompuFlo injection technology.

12 Nov 2010

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

Forest Laboratories, Inc. announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, on behalf of Janssen Inc., which will market the products in Canada.

12 Nov 2010

Diabetic drug may retard growth of fluid-filled cysts in PKD: Research

Researchers report that a drug commonly used to treat diabetes may also retard the growth of fluid-filled cysts of the most common genetic disorder, polycystic kidney disease.

12 Nov 2010

COMP issues positive opinion for Celsion's ThermoDox Orphan Drug Designation

Celsion Corporation, a leading oncology drug development company, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on the application for Orphan Drug Designation for ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer.

12 Nov 2010

FDA grants SEDASYS System appeal

Ethicon Endo-Surgery, Inc. (EES) today announced that the Commissioner's Office of the U.S. Food and Drug Administration (FDA) has granted the appeal of the Center for Devices and Radiological Health's (CDRH) denial of the SEDASYS System Premarket Approval Application (PMA). As a result, a new Independent Advisory Panel will be appointed to reconsider the SEDASYS System clinical trial data and application.

11 Nov 2010

G20 summit opens in Seoul; development plan announcement expected

The world's biggest rich and emerging powers escalated a war of words over trade and currencies Thursday, as leaders opened a G20 summit [in Seoul, South Korea] struggling to iron out distortions that threaten global growth, Agence France-Presse reports in an article examining some of the major disputes.

11 Nov 2010